Acting Commissioner of the Food and Drug Administration (FDA) Andrew von Eschenbach waits during the announcement of the approval of Atripla, the first one-pill, once-a-day product to treat HIV/AIDS patients during a news conference in Washington, July 12, 2006. REUTERS/Jim Young (UNITED STATES)